As a Practice Lead at DRG Ruth has responsibility for bringing strategic insights to client solutions provided by our expert teams. With a specialist interest in, and overall responsibility for, health technology assessment (HTA) services at DRG including global HTA submissions and strategy, early scientific advice, and local payer case for need applications. Ruth has been extensively involved in the development and strategic direction of HTAs, contributing in-depth knowledge of evidence requirements and procedural processes. With extensive experience of managing HTA submissions, Ruth works closely with our clients and in-house team, advising manufacturers on their role and requirements, and significantly contributes in the development and communication of HTA strategy and evidence generation planning from an early stage. Ruth joined DRG Abacus from the National Institute for Health and Care Excellence (NICE) in 2009 having been involved in technology appraisals and in the development of clinical guidelines as a health economist. With over 14 years’ experience in health outcomes research, Ruth’s experience covers a wide range of therapeutic areas including, oncology (cervical cancer, head and neck cancer, colorectal cancer, breast cancer), respiratory disease, HIV, hepatitis, gynaecology, gastroenterology, dermatology and orphan conditions. Ruth has an MSc in Health Economics from the University of York.